医学
多发性骨髓瘤
光学(聚焦)
重症监护医学
癌症研究
免疫学
光学
物理
作者
Бо Лю,Clifton C. Mo,Monique Hartley-Brown,Adam S. Sperling,Shonali Midha,Andrew J. Yee,Giada Bianchi,C. Piper,Alice Tattersall,Omar Nadeem,Jacob P. Laubach,Paul G. Richardson
标识
DOI:10.1080/17474086.2024.2382897
摘要
Introduction The treatment of multiple myeloma (MM) is evolving rapidly. Quadruplet regimens incorporating proteasome inhibitors, immunomodulatory drugs (IMiDs), and CD38 monoclonal antibodies have emerged as standard-of-care options for newly diagnosed MM, and numerous novel therapies have been approved for relapsed/refractory MM. However, there remains a need for novel options in multiple settings, including refractoriness to frontline standards of care.
科研通智能强力驱动
Strongly Powered by AbleSci AI